Bacterial Artificial Chromosome Reverse Genetics Approaches for SARS-CoV-2.
Bacterial artificial chromosome
COVID-19
Coronavirus
Infectious clone
Recombinant virus
Reverse genetics
SARS-CoV-2
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2024
2024
Historique:
medline:
8
12
2023
pubmed:
8
12
2023
entrez:
8
12
2023
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new member of the Coronaviridae family responsible for the coronavirus disease 19 (COVID-19) pandemic. To date, SARS-CoV-2 has been accountable for over 624 million infection cases and more than 6.5 million human deaths. The development and implementation of SARS-CoV-2 reverse genetics approaches have allowed researchers to genetically engineer infectious recombinant (r)SARS-CoV-2 to answer important questions in the biology of SARS-CoV-2 infection. Reverse genetics techniques have also facilitated the generation of rSARS-CoV-2 expressing reporter genes to expedite the identification of compounds with antiviral activity in vivo and in vitro. Likewise, reverse genetics has been used to generate attenuated forms of the virus for their potential implementation as live-attenuated vaccines (LAV) for the prevention of SARS-CoV-2 infection. Here we describe the experimental procedures for the generation of rSARS-CoV-2 using a well-established and robust bacterial artificial chromosome (BAC)-based reverse genetics system. The protocol allows to produce wild-type and mutant rSARS-CoV-2 that can be used to understand the contribution of viral proteins and/or amino acid residues in viral replication and transcription, pathogenesis and transmission, and interaction with cellular host factors.
Identifiants
pubmed: 38064031
doi: 10.1007/978-1-0716-3533-9_9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
133-153Informations de copyright
© 2024. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Andersen KG et al (2020) The proximal origin of SARS-CoV-2. Nat Med 26(4):450–452
pubmed: 32284615
pmcid: 7095063
doi: 10.1038/s41591-020-0820-9
Lu R et al (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395(10224):565–574
pmcid: 7159086
doi: 10.1016/S0140-6736(20)30251-8
Ksiazek TG et al (2003) A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348(20):1953–1966
pubmed: 12690092
doi: 10.1056/NEJMoa030781
Peiris JS et al (2003) Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361(9366):1319–1325
pubmed: 12711465
doi: 10.1016/S0140-6736(03)13077-2
van Boheemen S et al (2012) Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 3(6):e00473
Zaki AM et al (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367(19):1814–1820
pubmed: 23075143
doi: 10.1056/NEJMoa1211721
Alfaraj SH et al (2019) Clinical predictors of mortality of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: a cohort study. Travel Med Infect Dis 29:48–50
pubmed: 30872071
pmcid: 7110962
doi: 10.1016/j.tmaid.2019.03.004
Gudbjartsson DF et al (2020) Spread of SARS-CoV-2 in the Icelandic population. N Engl J Med 382(24):2302–2315
pubmed: 32289214
doi: 10.1056/NEJMoa2006100
Petersen E et al (2020) Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dise 20(9):e238–e244
Sikkema RS et al (2019) Global status of Middle East respiratory syndrome coronavirus in dromedary camels: a systematic review – CORRIGENDUM. Epidemiol Infect 147:e198
pubmed: 31364519
pmcid: 6536756
doi: 10.1017/S0950268819000669
Sarkar M, Madabhavi I (2022) SARS-CoV-2 variants of concern: a review. Monaldi Arch Chest Dis 93(3):2337
Ahmad A, Fawaz MAM, Aisha A (2022) A comparative overview of SARS-CoV-2 and its variants of concern. Infez Med 30(3):328–343
pubmed: 36148164
pmcid: 9448317
Ashoor D et al (2022) How concerning is a SARS-CoV-2 variant of concern? Computational predictions and the variants labeling system. Front Cell Infect Microbiol 12:868205
pubmed: 36034694
pmcid: 9399656
doi: 10.3389/fcimb.2022.868205
Bian L et al (2022) Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. Hum Vaccin Immunother 18(5):2057161
pubmed: 35438600
pmcid: 9115786
doi: 10.1080/21645515.2022.2057161
Mohapatra RK et al (2022) SARS-CoV-2 and its variants of concern including Omicron: a never ending pandemic. Chem Biol Drug Des 99(5):769–788
pubmed: 35184391
pmcid: 9111768
doi: 10.1111/cbdd.14035
Rabaan AA et al (2022) A comprehensive review on the current vaccines and their efficacies to combat SARS-CoV-2 variants. Vaccines (Basel) 10(10):1655
Khare S et al (2022) SARS-CoV-2 vaccines: types, working principle, and its impact on thrombosis and gastrointestinal disorders. Appl Biochem Biotechnol 195:1541–1573
Liang HY et al (2022) SARS-CoV-2 variants, current vaccines and therapeutic implications for COVID-19. Vaccines (Basel) 10(9)
Mahmood A et al (2022) Acute adverse effects of vaccines against SARS-COV-2. Cureus 14(7):e27379
pubmed: 36046318
pmcid: 9418632
Park H et al (2022) Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines. J Microbiol 60(3):308–320
pubmed: 35235179
pmcid: 8890016
doi: 10.1007/s12275-022-1598-x
Sendi P et al (2022) First-generation oral antivirals against SARS-CoV-2. Clin Microbiol Infect 28(9):1230–1235
pmcid: 9080050
doi: 10.1016/j.cmi.2022.04.015
Moreno S et al (2022) Use of antivirals in SARS-CoV-2 infection critical review of the role of remdesivir. Drug Des Devel Ther 16:827–841
pubmed: 35370401
pmcid: 8965332
doi: 10.2147/DDDT.S356951
Nappi F, Iervolino A, Avtaar Singh SS (2022) Molecular insights of SARS-CoV-2 antivirals administration: a balance between safety profiles and impact on cardiovascular phenotypes. Biomedicine 10(2):437
Mabrouk MT et al (2022) Advanced materials for SARS-CoV-2 vaccines. Adv Mater 34(12):e2107781
doi: 10.1002/adma.202107781
Wu F et al (2020) A new coronavirus associated with human respiratory disease in China. Nature 579(7798):265–269
pubmed: 32015508
pmcid: 7094943
doi: 10.1038/s41586-020-2008-3
Almazan F et al (2014) Coronavirus reverse genetic systems: infectious clones and replicons. Virus Res 189:262–270
pubmed: 24930446
doi: 10.1016/j.virusres.2014.05.026
Enjuanes L et al (2006) Biochemical aspects of coronavirus replication and virus-host interaction. Annu Rev Microbiol 60:211–230
pubmed: 16712436
doi: 10.1146/annurev.micro.60.080805.142157
Zhu N et al (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382(8):727–733
pubmed: 31978945
pmcid: 7092803
doi: 10.1056/NEJMoa2001017
Nogales A et al (2022) Mutation L319Q in the PB1 polymerase subunit improves attenuation of a candidate live-attenuated influenza a virus vaccine. Microbiol Spectr 10(3):e0007822
pubmed: 35583364
doi: 10.1128/spectrum.00078-22
Ye C et al (2020) Rescue of SARS-CoV-2 from a single bacterial artificial chromosome. MBio 11(5):e02168–e02120
pubmed: 32978313
pmcid: 7520601
doi: 10.1128/mBio.02168-20
Marquez-Jurado S et al (2018) An alanine-to-valine substitution in the residue 175 of zika virus NS2A protein affects viral RNA synthesis and attenuates the virus in vivo. Viruses 10(10)
Jangra S, et al (2021) The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera. medRxiv, 2021
Nogales A et al (2017) The K186E amino acid substitution in the canine influenza virus H3N8 NS1 protein restores its ability to inhibit host gene expression. J Virol 91(22):e00877-17
pubmed: 28835506
pmcid: 5660486
doi: 10.1128/JVI.00877-17
Perez DR et al (2017) Plasmid-based reverse genetics of influenza a virus. Methods Mol Biol 1602:251–273
pubmed: 28508225
doi: 10.1007/978-1-4939-6964-7_16
Nogales A et al (2016) Development and applications of single-cycle infectious influenza a virus (sciIAV). Virus Res 216:26–40
pubmed: 26220478
doi: 10.1016/j.virusres.2015.07.013
Kehrer T, et al (2022) Impact of SARS-CoV-2 ORF6 and its variant polymorphisms on host responses and viral pathogenesis. bioRxiv, 2022
Veleanu A et al (2022) Molecular analyses of clinical isolates and recombinant SARS-CoV-2 carrying B.1 and B.1.617.2 spike mutations suggest a potential role of non-spike mutations in infection kinetics. Viruses 14(9):2017
pubmed: 36146823
pmcid: 9506066
doi: 10.3390/v14092017
Chiem K et al (2022) Monitoring SARS-CoV-2 infection using a double reporter-expressing virus. Microbiol Spectr 10(5):e0237922
Chiem K, Nogales A, Martinez-Sobrido L (2022) Generation, characterization, and applications of influenza a reporter viruses. Methods Mol Biol 2524:249–268
pubmed: 35821477
doi: 10.1007/978-1-0716-2453-1_19
Ye C et al (2023) Immunization with recombinant accessory protein-deficient SARS-CoV-2 protects against lethal challenge and viral transmission. Microbiol Spectr 11(3):e00653-23
Martinez-Sobrido L, de la Torre JC (2016) Reporter-expressing, replicating-competent recombinant arenaviruses. Viruses 8(7):197
pubmed: 27447662
pmcid: 4974532
doi: 10.3390/v8070197
Breen M et al (2016) Replication-competent influenza a viruses expressing reporter genes. Viruses 8(7):179
pubmed: 27347991
pmcid: 4974514
doi: 10.3390/v8070179
Chiem K et al (2022) Identification of amino acid residues required for inhibition of host gene expression by influenza virus a/Viet Nam/1203/2004 H5N1 PA-X. J Virol 96(5):e0040821
pubmed: 33853954
doi: 10.1128/JVI.00408-21
Morales Vasquez D et al (2022) Bioluminescent and fluorescent reporter-expressing recombinant SARS-CoV-2. Methods Mol Biol 2524:235–248
pubmed: 35821476
doi: 10.1007/978-1-0716-2453-1_18
Ye C, Martinez-Sobrido L (2022) Generation of bi-reporter-expressing tri-segmented arenavirus. Methods Mol Biol 2524:223–233
pubmed: 35821475
pmcid: 10246865
doi: 10.1007/978-1-0716-2453-1_17
Chiem K et al (2021) Bi-reporter vaccinia virus for tracking viral infections in vitro and in vivo. Microbiol Spectr 9(3):e0160121
pubmed: 34817228
doi: 10.1128/Spectrum.01601-21
Morales Vasquez D et al (2021) Live imaging and quantification of viral infection in K18 hACE2 transgenic mice using reporter-expressing recombinant SARS-CoV-2. J Vis Exp 177:e63127
Ye C et al (2021) Analysis of SARS-CoV-2 infection dynamic in vivo using reporter-expressing viruses. Proc Natl Acad Sci U S A 118(41) e2111593118
Chiem K et al (2021) Amino acid residues involved in inhibition of host gene expression by influenza A/Brevig Mission/1/1918 PA-X. Microorganisms 9(5):1109
pubmed: 34065592
pmcid: 8160905
doi: 10.3390/microorganisms9051109
Nogales A, DeDiego ML, Martinez-Sobrido L (2022) Live attenuated influenza A virus vaccines with modified NS1 proteins for veterinary use. Front Cell Infect Microbiol 12:954811
pubmed: 35937688
pmcid: 9354547
doi: 10.3389/fcimb.2022.954811
Ye C, de la Torre JC, Martinez-Sobrido L (2020) Reverse genetics approaches for the development of mammarenavirus live-attenuated vaccines. Curr Opin Virol 44:66–72
pubmed: 32721864
pmcid: 7755828
doi: 10.1016/j.coviro.2020.06.011
Martinez-Sobrido L, DeDiego ML, Nogales A (2020) Reverse genetics approaches for the development of new vaccines against influenza A virus infections. Curr Opin Virol 44:26–34
Avila-Perez G et al (2020) In vivo rescue of recombinant Zika virus from an infectious cDNA clone and its implications in vaccine development. Sci Rep 10(1):512
pubmed: 31949262
pmcid: 6965646
doi: 10.1038/s41598-020-57545-2
Blanco-Lobo P et al (2019) Novel approaches for the development of live attenuated influenza vaccines. Viruses 11(2):190
Martinez-Sobrido L, de la Torre JC (2017) Development of recombinant arenavirus-based vaccines. Methods Mol Biol 1581:133–149
pubmed: 28374247
doi: 10.1007/978-1-4939-6869-5_8
Nogales A et al (2016) Rearrangement of influenza virus spliced segments for the development of live-attenuated vaccines. J Virol 90(14):6291–6302
pubmed: 27122587
pmcid: 4936145
doi: 10.1128/JVI.00410-16
Nogales A et al (2017) Canine influenza viruses with modified NS1 proteins for the development of live-attenuated vaccines. Virology 500:1–10
pubmed: 27750071
doi: 10.1016/j.virol.2016.10.008
Martinez-Sobrido L, de la Torre JC (2016) Novel strategies for development of hemorrhagic fever arenavirus live-attenuated vaccines. Expert Rev Vaccines 15(9):1113–1121
pubmed: 27118328
doi: 10.1080/14760584.2016.1182024
Baker SF, Nogales A, Martinez-Sobrido L (2015) Downregulating viral gene expression: codon usage bias manipulation for the generation of novel influenza A virus vaccines. Future Virol 10(6):715–730
pubmed: 26213563
pmcid: 4508661
doi: 10.2217/fvl.15.31
Cheng BY et al (2015) Arenavirus genome rearrangement for the development of live attenuated vaccines. J Virol 89(14):7373–7384
pubmed: 25972555
pmcid: 4473541
doi: 10.1128/JVI.00307-15
Cheng BY et al (2015) Development of live-attenuated arenavirus vaccines based on codon deoptimization. J Virol 89(7):3523–3533
pubmed: 25589652
pmcid: 4403387
doi: 10.1128/JVI.03401-14
Zhang Y et al (2022) A highly efficacious live attenuated mumps virus-based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike. Proc Natl Acad Sci U S A 119(33):e2201616119
pubmed: 35895717
pmcid: 9388148
doi: 10.1073/pnas.2201616119
Xie X et al (2021) Engineering SARS-CoV-2 using a reverse genetic system. Nat Protoc 16(3):1761–1784
pubmed: 33514944
pmcid: 8168523
doi: 10.1038/s41596-021-00491-8
Thi Nhu Thao T et al (2020) Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform. Nature 582(7813):561–565
pubmed: 32365353
doi: 10.1038/s41586-020-2294-9
Ye C et al (2020) Rescue of SARS-CoV-2 from a single bacterial artificial chromosome. MBio 11(5):e02168-20
Chiem K et al (2021) Generation and characterization of recombinant SARS-CoV-2 expressing reporter genes. J Virol 95(7):e02209–e02220
pubmed: 33431557
pmcid: 8092710
doi: 10.1128/JVI.02209-20
Chiem K, Ye C, Martinez-Sobrido L (2020) Generation of recombinant SARS-CoV-2 using a bacterial artificial chromosome. Curr Protoc Microbiol 59(1):e126
pubmed: 33048448
pmcid: 7646048
doi: 10.1002/cpmc.126
Almazán F et al (2006) Construction of a severe acute respiratory syndrome coronavirus infectious cDNA clone and a replicon to study coronavirus RNA synthesis. J Virol 80(21):10900–10906
pubmed: 16928748
pmcid: 1641757
doi: 10.1128/JVI.00385-06
Hotard AL et al (2012) A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. Virology 434(1):129–136
pubmed: 23062737
doi: 10.1016/j.virol.2012.09.022
Pu SY et al (2011) Successful propagation of flavivirus infectious cDNAs by a novel method to reduce the cryptic bacterial promoter activity of virus genomes. J Virol 85(6):2927–2941
pubmed: 21228244
pmcid: 3067970
doi: 10.1128/JVI.01986-10
Chiem K et al (2021) A bifluorescent-based assay for the identification of neutralizing antibodies against SARS-CoV-2 variants of concern in vitro and in vivo. J Virol 95(22):e0112621
pubmed: 34495697
doi: 10.1128/JVI.01126-21
Almazan F et al (2015) Engineering infectious cDNAs of coronavirus as bacterial artificial chromosomes. Methods Mol Biol 1282:135–152
pubmed: 25720478
doi: 10.1007/978-1-4939-2438-7_13
Almazan F et al (2013) Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate. MBio 4(5):e00650-13
pubmed: 24023385
pmcid: 3774192
doi: 10.1128/mBio.00650-13
Avila-Perez G et al (2019) Rescue of recombinant zika virus from a bacterial artificial chromosome cDNA clone. J Vis Exp 148:59537